BeOne Medicines Ltd. - Sponsored ADR

ONC Healthcare Biotechnology

BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024. In the quarter to June 2026, revenue grew 29.6%, EPS grew 143.7%, free cash flow grew 117.9% and total debt rose 503.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

369.06 5.02 −1.34%
Market cap
$39.0B
P/E
62.6×
Fwd P/E
40.2×
Dividend yield
—
F-score
7/9
Altman Z
5.25
Beneish M
−2.73
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Net Income
(119.22) (93.30) (674.03) (950.58) (1,600.52) (1,457.82) (2,003.81) (881.71) (644.79) 286.93
Operating Cash Flow
(89.51) 12.75 (547.72) (750.27) (1,283.46) (1,298.72) (1,496.62) (1,157.45) (140.63) 1,127.58
Investing cash flow
(221.85) (356.32) (637.61) 554.16 (3,168.37) 640.66 1,077.12 60.00 (548.35) (276.15)
Financing cash flow
380.90 490.36 1,690.54 85.68 5,202.83 3,636.91 (18.97) 416.48 193.45 1,059.45
Ending Cash
87.51 239.60 740.71 620.78 1,390.01 4,382.89 3,875.04 3,185.98 2,638.75 4,609.65
Other line items

Show all line items

In millions of $ except per-share values · columns are period end dates